Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ramosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 1.00 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 1.00 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 1.00 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 1.00 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ramosetron SCHEMBL9048400 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Ramosetron SCHEMBL1649718 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Ramosetron SCHEMBL8544326 | 0.99 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Ramosetron SCHEMBL1171445 | 0.98 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Ramosetron SCHEMBL9052281 | 0.94 | HTR3A (0.89) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Ramosetron SCHEMBL9048670 | 0.94 | HTR3A (0.89) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Ramosetron SCHEMBL9048395 | 0.92 | HTR3A (0.84) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Ramosetron SCHEMBL13531398 | 0.92 | HTR3A (0.84) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Ramosetron SCHEMBL16701 | 0.92 | HTR3A (0.84) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Ramosetron SCHEMBL2021739 | 0.92 | HTR3A (0.84) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5344927-A | 5-HT3 antagonist | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-09-06 | — | — | US | claimed |
| JP-3223278-A | — | — | None | — | — | JP | disclosed |
| CN-105669655-A | Synthesis method of Ramosetron | 苏州艾缇克药物化学有限公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20090203792-A1 | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1152761-B1 | USE OF 5-HT3 RECEPTOR ANTAGONISTS FOR TREATING MUSCULOESKELETAL DISEASES | NOVASEARCH AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| WO-2009033305-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR THE TEATMENT OF MYOCARDIAL INFARCTION, THROMBOSIS AND ATHEROSCLEROSIS | NOVASEARCH AG (CH) | 2009-03-19 | — | — | WO | disclosed |
| EP-2033632-A1 | 5-HT3 receptor antagonists for the teatment of myocardial infarction, stroke, thrombosis and atherosclerosis | Novasearch AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-7393857-B2 | Use of 5-HT3 receptor antagonists for treating musculoskeletal diseases | NOVASEARCH AG (CH) | 2008-07-01 | — | — | US | disclosed |
| EP-1480631-B1 | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING ALPHA2-DELTA- SUBUNIT CALCIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2000048597-A1 | SYSTEMIC USE OF 5-HT3 RECEPTOR ANTAGONISTS AGAINST RHEUMATIC INFLAMMATORY PROCESSES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| US-5985866-A | Use of serotonin antagonists for treating fibromyalgia | NOVARTIS AG (CH) | 1999-11-16 | — | — | US | disclosed |
| US-5773436-A | Use of serotonin antagonists for treating fibromyalgia | NOVARTIS AG (CH) | 1998-06-30 | — | — | US | disclosed |
| EP-0381422-B1 | Tetrahydrobenzimidazole derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5496942-A | 5-HT3-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| US-5344927-A | 5-HT3 antagonist | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| US-5225407-A | Cognition activators | GLAXO GROUP LIMITED (GB) | 1993-07-06 | — | — | US | disclosed |
| EP-0450757-A2 | Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood | GLAXO GROUP LIMITED (GB) | 1991-10-09 | — | — | EP | disclosed |
| JP-H03223278-A | TETRAHYDROBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUT CO LTD | 1991-10-02 | — | — | JP | disclosed |
| EP-0381422-A1 | Tetrahydrobenzimidazole derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | CACNB2, RYR2, FABP2 | HTR3A 928/4885HTR3E 1316/4885HTR3B 756/4885 |
| US-20090203792-A1 | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS | GABRB2, CACNA1D, CACNA1B | HTR3A 468/4885HTR3E 2200/4885HTR3B 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.